Myeloma

The latest news, research, and perspectives in multiple myeloma. Myeloma is a hematologic malignancy characterized by the proliferation of malignant plasma cells that produce monoclonal immunoglobulin. These neoplastic cells result in characteristic clinical features that include bone lytic lesions, hypercalcemia, renal insufficiency, and anemia.

Overview
Cecilia BrownMyeloma | December 2, 2022
Iberdomide plus dexamethasone showed encouraging efficacy and safety in triple-class-exposed R/R myeloma anti-BCMA therapy.
Read More
Cecilia BrownMyeloma | December 2, 2022
A GPRC5D-targeted autologous chimeric antigen receptor (CAR) T-cell therapy had “promising” preliminary efficacy.
Leah SherwoodMyeloma | December 1, 2022
At Blood Cancers Today, we have compiled the year's top content awards as doled out by the Twitterverse. 
Cecilia BrownMyeloma | November 15, 2022
No dose-limiting toxicities occurred in patients with relapsed/refractory multiple myeloma who were treated with agenT-797...
Cecilia BrownMyeloma | November 9, 2022
Findings support daratumumab plus lenalidomide and dexamethasone treatment for at least 18 months in MM...
Cecilia BrownMyeloma | November 9, 2022
Ciltacabtagene autoleucel led to responses in 61.5% of patients with multiple myeloma...
Leah SherwoodMyeloma | November 8, 2022
The phase III DREAMM-3 trial did not meet its primary endpoint...
Cecilia BrownTransplantation & Cellular Therapy | November 4, 2022
A GPRC5D-targeted CAR T-cell therapy led to a 71% response rate in patients with heavily pretreated multiple myeloma...
Leah SherwoodMyeloma | October 25, 2022
The FDA has granted accelerated approval for the use of teclistamab in adults with relapsed or refractory multiple myeloma.
Leah SherwoodMyeloma | October 25, 2022
Health-related quality of life improved in patients with R/R MM following treatment with the CAR T-cell treatment...
Kerri FitzgeraldMyeloma | October 14, 2022
A single infusion of ciltacabtagene autoleucel led to impressive overall response rates...
Kerri FitzgeraldMyeloma | October 14, 2022
A new study suggests the current reference intervals for serum free light chain concentrations...
Kerri FitzgeraldMyeloma | October 14, 2022
Talquetamab demonstrated “highly promising efficacy” in heavily pretreated patients with...
Cecilia BrownMyeloma | October 13, 2022
The phase I/II MajesTEC-1 study demonstrated that teclistamab produced a high rate of deep...
Cecilia BrownMyeloma | October 13, 2022
We are entering the great era of immunotherapy in multiple myeloma, as we’ve had significant...
Cecilia BrownMyeloma | October 13, 2022
The European Commission (EC) has granted marketing authorization for melphalan flufenamide...
Cecilia BrownMyeloma | October 13, 2022
The European Commission granted Conditional Marketing Authorization for teclistamab as a...
Leah SherwoodMyeloma | October 10, 2022
The committee overwhelmingly voted that melphalan flufenamide has not demonstrated benefit...
Leah SherwoodMyeloma | September 30, 2022
Blood Cancers Today Editor-in-Chief Sagar Lonial, MD, FACP, provides an update...
Kerri FitzgeraldMyeloma | September 13, 2022
Antibiotic prophylaxis should be considered an option for patients with newly diagnosed multiple myeloma...
Kerri FitzgeraldMyeloma | September 13, 2022
This triplet combination is safe and effective in patients with relapsed/refractory multiple myeloma...
Leah SherwoodMyeloma | September 12, 2022
CART-ddBCMA demonstrated a 100% overall response rate in patients with relapsed/refractory multiple myeloma.
Leah SherwoodMeeting News | September 12, 2022
Patients with both multiple myeloma (MM) and secondary immunodeficiencies (SID) face...
Cecilia BrownMyeloma | September 2, 2022
Ciltacabtagene autoleucel led to an overall response rate of nearly 98% in heavily pretreated...
Cecilia BrownMyeloma | September 2, 2022
A triplet treatment plus autologous stem-cell transplantation was associated with longer progression...
Cecilia BrownMyeloma | September 2, 2022
Treatment with teclistamab, a T-cell–redirecting bispecific antibody, led to a “high rate of deep and durable...
Cecilia BrownMyeloma | August 30, 2022
Doris Hansen, MD, of the Moffitt Cancer Center, spoke about the research during an oral abstract presentation at IMS.
Leah SherwoodMeeting News | August 30, 2022
Adding a monoclonal antibody to a triplet treatment significantly lowered the risk of disease...
Leah SherwoodMyeloma | August 30, 2022
A single infusion of ciltacabtagene autoleucel “resulted in deep and durable responses” in...
Leah SherwoodMyeloma | August 27, 2022
The data were from the phase III DETERMINATION trial...
Leah SherwoodMyeloma | August 26, 2022
Carfilzomib, lenalidomide, and dexamethasone improved progression-free survival (PFS) over...
Cecilia BrownMeeting News | August 26, 2022
Adding ixazomib to pomalidomide and dexamethasone improved progression-free survival rates...
Leah SherwoodAcute Myeloid Leukemia | August 16, 2022
The report showed significant demographic and geographic imbalances in pivotal clinical trials leading to drug approval.
Leah SherwoodMyeloma | August 1, 2022
The European Commission (EC) has granted marketing authorization for selinexor, an oral exportin 1 inhibitor...
Leah SherwoodMyeloma | July 29, 2022
The EMA’s CHMP recommendation is based on positive results from the multicohort, open-label...
Cecilia BrownMyeloma | July 22, 2022
The benefit of maintenance therapy with ixazomib after allogenic hematopoietic stem cell transplantation...
Leah SherwoodMyeloma | July 18, 2022
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use issued...
Leah SherwoodMyeloma | July 7, 2022
The genetic signature consists of the genes WNT10A, DUSP1, and ETV7...
Leah SherwoodMyeloma | July 6, 2022
QXL138AM is a masked immunocytokine comprised of a CD138-targeted antibody fused with...
Leah LawrenceMyeloma | June 27, 2022
The use of the CD38-directed monoclonal antibody daratumumab was associated with ocular events...
Kerri FitzgeraldAcute Myeloid Leukemia | June 23, 2022
The FDA has cleared the IND application for LAVA-051, humanized Gammabody designed to activate...
Leah LawrenceChronic Lymphocytic Leukemia | June 23, 2022
LAVA-051 consists of two single domain antibodies linked via a short five amino acid glycine-serine linker.
Leah SherwoodMyeloma | June 21, 2022
The ORR was 96%, including 92% at the level of VGPR, and the MRD negativity rate was 62%...
Leah SherwoodMyeloma | June 21, 2022
Among 37 evaluable patients, the ORR was 78%, and 27 patients had a VGPR or better...
Leah LawrenceMyeloma | June 8, 2022
In myeloma, isatuximab plus carfilzomib and dexamethasone (Isa-Kd) resulted in clinically improved...
Leah LawrenceMyeloma | June 8, 2022
IgD myeloma constitutes about 1% of myelomas and has worse prognosis than other subtypes...
Kerri FitzgeraldMyeloma | June 6, 2022
Belantamab mafodotin is a BCMA targeted antibody drug conjugate approved for adult patients...
Leah LawrenceMyeloma | May 31, 2022
The study explored adding daratumumab to RVd and VTd regimens for patients with multiple myeloma...
Leah LawrenceMyeloma | May 26, 2022
The median PFS with the three-drug combination was higher compared with carfilzomib and dexamethasone alone.
Kerri FitzgeraldMyeloma | May 24, 2022
Authors provide a case that demonstrates the real-world challenges of managing older, frail adults with newly diagnosed MM.
Kerri FitzgeraldMyeloma | May 24, 2022
Peter M. Voorhees, MD, of the Levine Cancer Institute at Atrium Health, and Thomas Martin, MD, of the University of ...
Leah LawrenceMyeloma | May 19, 2022
A small study observed a link between BMI and progression of monoclonal gammopathy of undetermined significance.
Leah LawrenceMyeloma | May 19, 2022
This finding comes despite the fact that the same three-drug combination improved overall survival in the relapsed/refractory ...
Leah LawrenceMyeloma | May 12, 2022
Adding ixazomib to this treatment regimen did not improve survival outcomes, according to results of the MUKeight trial
Leah LawrenceMyeloma | May 12, 2022
A study has identified a very high prevalence of all monoclonal gammopathies in high-risk individuals aged 50 years or older.
Leah LawrenceMyeloma | May 10, 2022
A study identified differences in molecular features that may drive clinical disparities seen in patients with myeloma.
Leah LawrenceMyeloma | May 5, 2022
Few patients with myeloma benefit from CAR-T cell therapy, according to a Viewpoint.
Ariel DeMaioMyeloma | May 3, 2022
Findings support the use of MRD negativity as a prognostic tool to measure deep response, leading to improved PFS.
Leah LawrenceMyeloma | May 2, 2022
A phase I study is underway to assess ALLO-605.
Leah LawrenceMyeloma | April 25, 2022
Minimal residual disease (MRD) negativity after autologous hematopoietic cell transplantation (AHCT) was associated with ...
Leah LawrenceMyeloma | April 22, 2022
Study finds that a third dose of the COVID-19 vaccine increased antibodies in multiple myeloma patients, regardless of prior ...
Leah LawrenceMyeloma | April 21, 2022
Immune checkpoint inhibitors can lower the risk of developing neurologic adverse events (NAEs) more than other cancer ...
Sabrina AhleMyeloma | March 22, 2022
New legislation would set time limits around FDA accelerated approvals.
Sabrina AhleMyeloma | March 12, 2022
According to a recent HHS report, the percentage of uninsured Black Americans has decreased since the ACA became law in 2010.
Sabrina AhleMyeloma | March 12, 2022
Cilta-cel has been approved by the FDA for the treatment of patients with relapsed or refractory multiple myeloma who have ...
Leah LawrenceTransplantation & Cellular Therapy | March 2, 2022
With increasing evidence of efficacy as front-line treatment in relapsed/refractory disease, clinicians are excited to see ...
Patrick DalyMyeloma | March 2, 2022
Teclistamab produced meaningful and durable responses in patients with heavily pretreated relapsed or refractory multiple ...
Ariel DeMaioAggressive B-Cell Lymphoma | March 2, 2022
Pivotal trials that supported FDA approval of CAR T-cell therapies had low proportions of Black patients enrolled.
Brandon MayMyeloma | March 2, 2022
Researchers explored whether population-based screening for MGUS could increase the frequency of patients with multiple ...
Sabrina AhleMyeloma | March 2, 2022
Post-transplant response-adapted consolidation therapy with Dara-KRd using MRD led to high rates of MRD negativity in ...
Sagar Lonial, MD, FACPMyeloma | March 2, 2022
Welcome to the second issue of Blood Cancers Today, where we’re continuing to share stories and updates on data that ...
Jacob Laubach, MD, MPPMyeloma | February 24, 2022
Jacob Laubach, MD, MPP, from Dana-Farber Cancer Institute, shares his thoughts.
Jacob Laubach, MD, MPPMyeloma | February 24, 2022
Dr. Laubach, from Dana-Farber Cancer Institute, reviews follow-up data from the phase II GRIFFIN trial.
Sabrina AhleMyeloma | February 22, 2022
Patients with hematologic malignancies have a significantly higher rate of composite thrombotic outcomes during acute ...
Sabrina AhleAcute Lymphoblastic Leukemia | February 8, 2022
Researchers have discovered that chemotherapy and COVID-19 infection cause neuro-inflammation in similar ways.
Sagar Lonial, MD, FACPMyeloma | February 2, 2022
Editor-in-Chief Sagar Lonial, MD, FACP, introduces the new publication from SOHO.
Susan O'Brien, MDAcute Lymphoblastic Leukemia | February 1, 2022
At SOHO 2021, Susan O'Brien, MD, and Hagop Kantarjian, MD, addressed trends in hematologic malignancies.
Sabrina AhleMyeloma | January 21, 2022
Daratumumab and hyaluronidase-fihj, in combination with carfilzomib and dexamethasone (Kd), has received U.S. Food and Drug ...
Sagar Lonial, MD, FACPMyeloma | January 21, 2022
The pace of change in blood cancers is quite dramatic, and new paradigms of treatment, assessment, and pathogenesis occur ...
Noopur Raje, MDMyeloma | January 15, 2022
Noopur Raje, MD, is the Director of the Multiple Myeloma Program at Massachusetts General Hospital.
Noopur Raje, MDMyeloma | January 15, 2022
Noopur Raje, MD, discusses the safety and efficacy results of the CRB-402 trial.
Rebecca AraujoMyeloma | November 19, 2021
In a study, researchers sought to calculate healthcare costs associated with triple class exposure (TCE) to multiple myeloma ...
Rebecca AraujoMantle Cell Lymphoma | November 15, 2021
Patients in the trial were treated for lymphoma, leukemia, or multiple myeloma.
Rebecca AraujoHodgkin Lymphoma | November 12, 2021
Older patients (over 65) with cancer receiving immune checkpoint inhibitors (ICIs) are at a significantly increased risk of ...
Rebecca AraujoMyeloma | October 26, 2021
A study published in Internal Medicine evaluated the safety profile of ixazomib in a cohort of Japanese patients with ...
Rob DillardMyeloma | October 21, 2021
Researchers sought to discern the effect of COVID-19 countermeasures on treatment outcomes in a patient population receiving ...
Myeloma | October 21, 2021
Several factors are correlated with palliative care use among patients with various cancers, but literature is lacking on ...
Sabrina AhleMyeloma | October 21, 2021
The LocoMMotion study provides real-world data on outcomes in triple-class exposed MM patients receiving standard of care.
Vikas A. Gupta, MD, PhDMyeloma | October 21, 2021
Vikas A. Gupta, MD, PhD and Lawrence H. Boise, PhD ...
Faith Davies, MBBCh, MD MRCP, MRCPathMyeloma | October 21, 2021
Faith Davies, MBBCh, MD MRCP, MRCPath ...
Rebecca AraujoMyeloma | October 18, 2021
In a phase II prospective clinical trial, researchers evaluated the effectiveness of a personalized sequential therapy for ...
Rebecca AraujoMyeloma | October 18, 2021
A study published in Environment International reported an elevated risk of multiple myeloma (MM) among female agricultural ...
Rebecca AraujoAcute Lymphoblastic Leukemia | October 11, 2021
A study evaluated factors associated with intense end-of-life care among patients younger than 40 with blood cancer.
Rob DillardMyeloma | October 5, 2021
Researchers of a study investigated the relationship between chronic kidney disease and multiple myeloma (MM) in a South ...
Rebecca AraujoTransplantation & Cellular Therapy | September 28, 2021
Black patients with multiple myeloma (MM) who receive upfront hematopoietic autologous cell transplantation (ASCT) have ...
Rebecca AraujoChronic Lymphocytic Leukemia | September 24, 2021
A study published in Cancer Causes & Control evaluated racial differences in individual- and geographic-level factors among ...
Rebecca AraujoT-Cell Lymphoma | September 23, 2021
Previous studies have shown that Black patients with some blood cancers are at increased risk for blood clots. A research ...
Rob DillardMyeloma | September 7, 2021
Socioeconomic status (SES) and race/ethnicity should be considered when planning multiple myeloma (MM) interventions, ...
Rob DillardMyeloma | September 7, 2021
Socioeconomic factors play a big role in multiple myeloma (MM) disparities, according to a study published in ...
Rebecca AraujoMyeloma | August 31, 2021
A study published in Blood Advances found that a gene linked to multiple myeloma (MM) prognosis is expressed less frequently ...
Rebecca AraujoMyeloma | August 31, 2021
A study published in JCO Global Oncology evaluated mid-to long-term outcomes of multiple myeloma (MM) treatment in Peru. ...
Rebecca AraujoMyeloma | August 23, 2021
A study of patients with multiple myeloma (MM) in Latin America found that major bone complications are linked to increased ...
Rebecca AraujoTransplantation & Cellular Therapy | August 23, 2021
A study published in Bone Marrow Transplantation evaluated whether patient characteristics impacted the timeline to return to ...
Elisa S. Weiss, PhDMyeloma | August 18, 2021
Elisa S. Weiss, PhD, Senior Vice President, Education, Services & Health Research, LLS, New York ...
Manisha Bhutani, MDMyeloma | August 18, 2021
Redefining Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma ...
Myeloma | August 18, 2021
Zainab Shahid, MD, FACP, and Shaji K. Kumar, MD ...
Urvi A. Shah, MDMyeloma | August 18, 2021
Urvi A. Shah, MD, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York ...
Saad Z. Usmani, MD, MBA, FACPMyeloma | August 18, 2021
Experts focus on the latest news and clinical development and impact for multiple myeloma.
Saad Z. Usmani, MD, MBA, FACPMyeloma | August 18, 2021
Experts discuss treatment options related to anti-CD38 based combination triplets.
Myeloma | August 18, 2021
Ola Landgren, MD, PhD, Myeloma Service, Sylvester Comprehensive Cancer Center, University of Miami ...
María-Victoria Mateos, MD, PhDMyeloma | August 17, 2021
María-Victoria Mateos, MD, PhD, Borja Puertas MD, and Veronica González-Calle MD, PhD ...
Rob DillardTransplantation & Cellular Therapy | August 12, 2021
The use of hematopoietic stem cell transplantation (AHCT) is associated with excellent 2-year outcomes in multiple myeloma ...
Rob DillardAggressive B-Cell Lymphoma | August 10, 2021
A cross-sectional survey study involved patients treated in Mexico City for lymphoma, leukemia, or multiple myeloma.
Saad Z. Usmani, MD, MBA, FACPMyeloma | August 6, 2021
Drs. Saad Usumani and Sydney Lu discuss adjusting multiple myeloma treatments to the realities of the COVID-19 pandemic.
Rob DillardMyeloma | August 6, 2021
A study found no discernible difference in the usage rate of hematopoietic cell transplantation (HCT) between Black and White ...
Rob DillardMyeloma | July 29, 2021
A recent study shows that multiple sites of extramedullary-bone related (EMB) lesions are poor prognostic factors for newly ...
Rob DillardMyeloma | July 27, 2021
A study found sex differences in high-risk cytogenetics among patients with multiple myeloma (MM), though these differences ...
Rob DillardMyeloma | July 27, 2021
Clarithromycin plus lenalidomide and dexamethasone for the treatment of multiple myeloma (MM) did not offer a survival ...
Rob DillardMyeloma | July 26, 2021
Patient race and ethnicity were bound to be associated with hematopoietic stem/progenitor cells (HSPC) mobilization, ...
Rob DillardMyeloma | July 26, 2021
An analysis of Asian patients with multiple myeloma found that treatment with subcutaneous daratumumab (DARA SC) was ...
Rob DillardMyeloma | July 22, 2021
A study indicates that BCL2 dependence, as well as CD38 expression, are significantly linked with the differentiation ...
Rob DillardMyeloma | July 15, 2021
Elevated membrane expression of junctional adhesion molecule A (JAM-A) on multiple myeloma endothelial cells (MMECs) ...
Saad Z. Usmani, MD, MBA, FACPMyeloma | July 13, 2021
Communication between the clinician and patient, as a two-way conversation, clarity on goals for treatment and treatment ...
Saad Z. Usmani, MD, MBA, FACPMyeloma | July 7, 2021
Janssen and Legend Biotech announced new data for BCMA-directed CAR-T cell therapy cilta-cel for relapsed/refactory MM.
Rob DillardMyeloma | June 30, 2021
Researchers for a recent study evaluated the prevalence and characteristics of second primary malignancies (SPMs) in Black ...
Rob DillardTransplantation & Cellular Therapy | June 30, 2021
A study did not observe racial disparities in the use of autologous hematopoietic cell transplantation (HCT) consolidative ...
Rob DillardMyeloma | June 30, 2021
Insurance status was associated with survival among patients with multiple myeloma (MM), according to new study results ...
Rob DillardMyeloma | June 30, 2021
A new study reports on county-level socioeconomic disparities in the distribution of multiple myeloma (MM) clinical trial ...
Rob DillardMyeloma | June 30, 2021
A study found that a high expression of the coding gene human leukocyte antigen-E (HLA-E) is associated with advanced disease ...
Rebecca AraujoMyeloma | June 14, 2021
Although physical activity and exercise programs have shown benefit for patients with multiple myeloma (MM), clinical ...
Rebecca AraujoMyeloma | June 11, 2021
In patients with multiple myeloma (MM), higher patient-rated pain severity was found to be significantly associated with ...
Rebecca AraujoMyeloma | June 7, 2021
Treatment with a regimen of bortezomib, melphalan, and prednisone (VMP) with or without daratumumab (D-VMP) led to similar ...
Rebecca AraujoMyeloma | June 7, 2021
Incidence of multiple myeloma (MM) has more than doubled globally since 1990, according to an analysis published in BMC ...
Rebecca AraujoMyeloma | May 24, 2021
Real-world data showed that upfront autologous hematopoietic stem cell transplantation (AHCT) for treatment of multiple ...
Rebecca AraujoMyeloma | May 17, 2021
A predictive tool may help primary care physicians identify patients at high-risk of multiple myeloma (MM), according to a ...
Rebecca AraujoMyeloma | May 17, 2021
Researchers from The Mount Sinai Health System in New York City evaluated racial disparities in time to autologous ...
Rebecca AraujoMyeloma | May 17, 2021
A study published in the Annals of Hematology used real-world evidence to conduct head-to-head comparisons of triplet ...
Rebecca AraujoMyeloma | May 10, 2021
A study published in Clinical Lymphoma, Myeloma, & Leukemia evaluated the efficacy of intravenous immunoglobin (IVIG) to ...
Saad Z. Usmani, MD, MBA, FACPMyeloma | April 27, 2021
Based on the LLS Professional Education Webcast: Multiple Myeloma: Diagnosis, Treatment, and Side Effects Management ...
Nikhil Munshi, MDTransplantation & Cellular Therapy | April 27, 2021
Nikhil Munshi, MD, had a conversation with Orsi Giricz, PhD, from LLS, to discuss the recent approval of Abecma and his role ...
Peter Voorhees, PhDMyeloma | April 27, 2021
Peter Voorhees, PhD ...
Rebecca AraujoMyeloma | April 26, 2021
A study from researchers at Sungkyunkwan University in Seoul, South Korea assessed how depression impacts ...
Rebecca AraujoMyeloma | April 21, 2021
A study published in The Lancet Haematology reviewed responses to the first dose of the SARS-CoV-2 vaccine in patients with ...
Douglas Sborov, MD, MSMyeloma | April 9, 2021
Douglas Sborov, MD, MS, discusses the impact of the COVID-19 pandemic on treatment and care for patients with MM.
Douglas Sborov, MD, MSMyeloma | April 9, 2021
Douglas Sborov, MD, speaks about recent initiatives to expand eligibility to multiple myeloma clinical trials.
Rebecca AraujoMyeloma | April 9, 2021
On March 10, 2021, the National Comprehensive Cancer Network Vaccination Advisory Committee released their recommendations ...
Rebecca AraujoMyeloma | April 2, 2021
On March 31, 2021, the FDA extended the indication of isatuximab for use in combination with carfilzomib and dexamethasone ...
Rebecca AraujoTransplantation & Cellular Therapy | March 30, 2021
The U.S. Food and Drug Administration (FDA) approved idecabtagene vicleucel (ide-cel) for the treatment of adults with ...
Rebecca AraujoMyeloma | March 11, 2021
A study published in the European Journal of Haematology calculated costs and survival outcomes associated with ...
Rebecca AraujoMyeloma | March 11, 2021
Two studies that assessed multiple myeloma care in Latin America found significant differences in access and outcomes ...
Rebecca AraujoTransplantation & Cellular Therapy | March 9, 2021
A study published in Clinical Lymphoma, Myeloma & Leukemia evaluated the burden of outpatient autologous hematopoietic ...
Rebecca AraujoMyeloma | March 9, 2021
A study published in BMC Medicine evaluated physical and mental health-related outcomes in patients with multiple myeloma ...
Parameswaran Hari, MDMyeloma | March 5, 2021
Parameswaran Hari, MD, weighs in on clinical considerations for selecting CAR T cell therapy for multiple myeloma.
Parameswaran Hari, MDMyeloma | March 4, 2021
Parameswaran Hari, MD, speaks about myeloma research presented at the virtual 2020 ASH Annual Meeting.
Rebecca AraujoMyeloma | March 4, 2021
A study published in the Journal of Medical Economics calculated costs associated with the use of different proteasome ...
Rebecca AraujoMyeloma | March 3, 2021
On March 1, 2021, the U.S. Food and Drug Administration granted accelerated approval to melphalan flufenamide (melflufen) in ...
Rebecca AraujoTransplantation & Cellular Therapy | March 2, 2021
The latest updates from the KarMMA trial, published in The New England Journal of Medicine, showed that treatment with ...
Rebecca AraujoMyeloma | March 2, 2021
Findings presented at the ASH 2020 Annual Meeting & Exposition found that almost half of patients with multiple myeloma (MM) ...
Myeloma | March 2, 2021
A study published online in the Journal of Oncology Pharmacy Practice calculated economic outcomes of patients with ...
Myeloma | March 2, 2021
An early access treatment protocol (EAP) found that daratumumab monotherapy was safe in a population of patients with heavily ...
Rebecca AraujoMyeloma | February 22, 2021
In a collaborative effort, researchers from the Dana-Farber Cancer Institute, the U.S. Food and Drug Administration, and the ...
Rebecca AraujoMyeloma | February 17, 2021
A study published in the British Journal of Cancer assessed whether esterase gene expression is of clinical significance in ...
Rebecca AraujoTransplantation & Cellular Therapy | February 17, 2021
Patients with multiple myeloma who underwent double autologous hematopoietic cell transplantation did not have better overall ...
Raj Chakraborty, MDMyeloma | February 16, 2021
Raj Chakraborty, MD, discusses how new research on treatments for multiple myeloma may impact the treatment landscape.
Raj Chakraborty, MDMyeloma | February 16, 2021
Raj Chakraborty, MD, speaks about considerations for selecting between BiTEs and CAR T-cell therapy.
Raj Chakraborty, MDMyeloma | February 16, 2021
Raj Chakraborty, MD, speaks about the benefits of antibody drug conjugates (ADC) for multiple myeloma.
Raj Chakraborty, MDMyeloma | February 8, 2021
Raj Chakraborty, MD, speaks about promising results from current clinical trials for newly diagnosed multiple myeloma.
Rebecca AraujoMyeloma | February 4, 2021
Therapeutic regimens for multiple myeloma that use a combination of the anti-CD38 monoclonal antibody daratumumab induce ...
Rebecca AraujoMyeloma | February 4, 2021
A study from researchers at the University of Pittsburgh and other institutions aimed to evaluate the pain experiences among ...
Rebecca AraujoMyeloma | February 3, 2021
In an analysis of real-world data, the all-oral triplet regimen of ixazomib, lenalidomide, and dexamethasone (IRD) for ...
Rebecca AraujoMyeloma | February 1, 2021
Real-world data from a single institution showed concerningly low levels of long-term adherence to lenalidomide therapy for ...
Rebecca AraujoMyeloma | January 22, 2021
An analysis of patients with multiple myeloma (MM) who underwent autologous hematopoietic cell transplant (AHCT) showed that ...
Rebecca AraujoMyeloma | January 22, 2021
A new study showed evidence of racial disparities in the use of intravenous (IV) bisphosphonates among older patients ...
Rebecca AraujoMyeloma | January 21, 2021
First-line daratumumab therapy for patients with transplant-ineligible multiple myeloma (MM) may not be cost-effective at the ...
Rebecca AraujoHodgkin Lymphoma | January 20, 2021
A research team in Norway found that previous hematological malignancies were associated with a subsequent diagnosis.
Rebecca AraujoMyeloma | January 11, 2021
ABO blood groups may play a role in the development and outcomes of multiple myeloma, according to new data published in ...
Rebecca AraujoMyeloma | January 8, 2021
A study of farmers found that exposure to certain pesticides was associated the development with monoclonal gammopathy of ...
Rebecca AraujoMyeloma | January 8, 2021
A study published in the British Journal of Haematology assessed updated survival data from a phase II trial of melphalan ...
Rebecca AraujoMyeloma | January 7, 2021
According to new data published in Blood, patients with multiple myeloma (MM) who are hospitalized for COVID-19 infection ...
Rebecca AraujoMyeloma | January 5, 2021
Iberdomide, an oral potent novel cereblon E3 ligase modulator (CELMoD), demonstrated an acceptable toxicity profile and ...
Rebecca AraujoMyeloma | January 5, 2021
Data presented at the 2020 ASH Annual Meeting showed that the addition of subcutaneous daratumumab to pomalidomide and ...
Rebecca AraujoTransplantation & Cellular Therapy | January 5, 2021
The novel chimeric antigen receptor (CAR) T cell therapy, CT053, achieved a 100% overall response rate (ORR) for the ...
Rebecca AraujoTransplantation & Cellular Therapy | January 5, 2021
Results from the PRIME study found that P-BCMA-101, an autologous CAR T-cell therapy, was effective and safe for patients ...
Ariel DeMaioMyeloma | January 5, 2021
Patients with high-risk myeloma may not be appropriately recognized as having high-risk disease at diagnosis, according to a ...
Rebecca AraujoMyeloma | January 5, 2021
Insurance status was found to be significantly associated with survival for patients with multiple myeloma, according to ...
Rebecca AraujoMyeloma | January 5, 2021
According to data presented at the 2020 ASH Annual Meeting, the use of direct oral anticoagulants effectively prevented ...
Myeloma | January 5, 2021
A study published in BMC Cancer analyzed the relationship between education level and survival in multiple myeloma and ...
Rebecca AraujoMyeloma | January 5, 2021
A study presented at the ASH Annual Meeting found that among 6 landmark multiple myeloma clinical trials, the ineligibility ...
Myeloma | December 2, 2020
Maintenance therapy increases survival in patients with multiple myeloma (MM) compared with observation, according to a study ...
Rebecca AraujoMyeloma | December 2, 2020
The addition of elotuzumab to lenalidomide and dexamethasone significantly improved survival outcomes in patients with ...
Myeloma | December 2, 2020
A study presented at the 2020 Society of Hematologic Oncology Annual Meeting found that the addition of ixazomib to ...
Nina Shah, MDMyeloma | December 2, 2020
Nina Shah, MD, discusses novel immunotherapy agents in development for multiple myeloma and what to know about them.
Nina Shah, MDMyeloma | December 2, 2020
Nina Shah, MD, talks about two multiple myeloma agents granted priority review by the FDA and data on these therapeutics.
Rob DillardTransplantation & Cellular Therapy | December 2, 2020
A study published in the Journal of Clinical Oncology found that ixazomib maintenance therapy extended survival in patients ...
Rob DillardMyeloma | December 2, 2020
A study published in Clinical Lymphoma, Myeloma & Leukemia evaluated the safety and efficacy of VD-PACE in combination with ...
Nina Shah, MDMyeloma | December 2, 2020
Nina Shah, MD, discusses immunotherapy agents in the pipeline for multiple myeloma.
Rob DillardChronic Lymphocytic Leukemia | December 2, 2020
The study included a cohort of 1044 adults with cancer who were enrolled in the UK Coronavirus Cancer Monitoring Project.
Rob DillardMyeloma | December 2, 2020
A study published in the Journal of Geriatric Oncology found that rates of no treatment and early mortality are higher in ...
Rob DillardMyeloma | December 2, 2020
A study published in Clinical Cancer Research confirmed that lenalidomide 10 mg to 15 mg per day is an effective dose to ...
Sarah Holstein, MD, PhDMyeloma | December 2, 2020
Sarah Holstein, MD, PhD, discusses the myeloma treatment pipeline and how these agents may change the treatment landscape.
Ariel DeMaioMyeloma | December 2, 2020
Researchers compared the efficacy of lenalidomide and dexamethasone paired with carfilzomib or bortezomib for the treatment ...
Saad Z. Usmani, MD, MBA, FACPMyeloma | December 2, 2020
Dr. Usmani discusses an indirect treatment comparison study which assesses daratumumab plus lenalidomide and dexamethasone.
Myeloma | December 2, 2020
In a head-to-head comparison of minimal residual disease (MRD) versus stringent complete response (sCR) to determine clinical ...
Sarah Holstein, MD, PhDMyeloma | December 2, 2020
Sarah Holstein, MD, PhD, talks about BCMA as a target of interest for multiple myeloma, as well as other emerging targets.
Rob DillardMyeloma | December 2, 2020
The addition of daratumumab to standard therapy improved responses in Black transplant-eligible patients with newly diagnosed ...
Rob DillardMyeloma | December 2, 2020
Venetoclax plus bortezomib and dexamethasone significantly improved survival compared with bortezomib and dexamethasone alone ...
Shaji Kumar, MDMyeloma | December 2, 2020
Shaji Kumar, MD, discusses B-cell maturation antigen as a target for myeloma and belantamab mafodotin.
Rob DillardMyeloma | December 2, 2020
Sarah Holstein, MD, PhD, discusses the lack of Black patients with multiple myeloma enrolled in clinical trials.
Shaji Kumar, MDMyeloma | December 2, 2020
The ENDURANCE trial assessed carfilzomib versus bortezomib plus lenalidomide and dexamethasone for newly diagnosed MM.
Rob DillardMyeloma | December 2, 2020
A study published in Blood identified the following factors as predictive of worse outcomes for patients with multiple ...
Shaji Kumar, MDMyeloma | December 2, 2020
Shaji Kumar, MD, highlighted how the treatment paradigm may change in the coming years.
Rob DillardMyeloma | December 2, 2020
Bortezomib-containing treatment regimens for myeloma are associated with an increased risk for tumor lysis syndrome (TLS) in ...
Myeloma | December 2, 2020
A study published in BMC Cancer analyzed the relationship between education level and survival in multiple myeloma and ...
Rebecca AraujoMyeloma | December 2, 2020
A study published in the Journal of Clinical Oncology assessed doublet versus triplet bortezomib-based therapy in patients ...
Rob DillardMyeloma | December 2, 2020
The phase III BOSTON study found that once-weekly selinexor, bortezomib, and dexamethasone is a novel, effective, and ...
Rob DillardMyeloma | December 2, 2020
Immune system cells and signal carriers amid the tumor cells undergo dramatic shifts, with alterations in both the number and ...
Rebecca AraujoMyeloma | December 2, 2020
A study published in JAMA Oncology found that the addition of daratumumab to backbone multiple myeloma regimens improved ...
Ankit Kansagra, MDMyeloma | December 2, 2020
Ankit Kansagra, MD, discusses chimeric antigen receptor T-cell agents in the pipeline for multiple myeloma.
Rebecca AraujoMyeloma | December 2, 2020
A study published in the Journal of Hematology & Oncology found that drug exposure and disease status do not impact mortality ...
Rebecca AraujoMyeloma | December 2, 2020
A study published in Cancer Science observed that isatuximab monotherapy was an effective and well-tolerated treatment for ...
Myeloma | December 2, 2020
A study using whole-genome sequencing data found that patients with multiple myeloma (MM) with low genomic scar score (GSS) ...
Rob DillardMyeloma | December 2, 2020
Patients with multiple myeloma receiving statins had reduced mortality, according to a study published in Clinical Lymphoma, ...
Advertisement
Advertisement
Advertisement
Latest News

November 15, 2022

Advertisement